Unicycive Therapeutics (UNCY) FCF Margin (2022 - 2023)
Unicycive Therapeutics' (UNCY) quarterly FCF Margin came in at 580.74% in Q1 2023, down 55.01% on a QoQ basis from 374.66% in Q3 2022.
Unicycive Therapeutics (UNCY) FCF Margin (2022 - 2023) Analysis & Trends
Unicycive Therapeutics (UNCY) has 2 years of FCF Margin data on file, last reported at 580.74% in Q1 2023.
- Quarterly FCF Margin changed N/A year-over-year to 580.74% in Q1 2023, while the trailing twelve-month figure through Dec 2023 was 2708.59% (changed N/A YoY) and the FY2023 annual result came in at 2710.37%, down 106442.0% from the prior year.
- FCF Margin retreated to 580.74% in Q1 2023, from 374.66% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 374.66% in Q3 2022 to a low of 580.74% in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.14 Bn | 132.29 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 87.02 Bn | 79.03 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 65.30 Bn | 60.12 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.84 Bn | 55.70 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 42.15 Bn | 37.06 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 31.49 Bn | 28.18 Bn | 992.69 Mn | 22.62% |
| 7 | BioNTech SE | 28.78 Bn | 10.38 Bn | 668.28 Mn | 41.07% |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | -22.35% |
| 9 | Royalty Pharma | 27.14 Bn | 26.31 Bn | - | 70.82% |
| 10 | Unicycive Therapeutics | 152.62 Mn | 152.62 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | -580.74% |
| Sep 30, 2022 | -374.66% |